Maedica · 2026
Orthoptek Magnocellular Stimulation for Amblyopia Across Age Groups: Visual Recovery Beyond Childhood.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shah Mehul, Shah Shreya, Morya Arvind Kumar, Aggarwal Sarita, Bose Sunandini, Anagha S, Gopal K Santhan
Аннотация
PURPOSE: To assess the outcome of Orthoptek Magnocellular Stimulator (OMS) therapy on visual acuity, binocular vision and stereopsis in patients with amblyopia across various age groups and to evaluate treatment efficacy.
METHODS: This prospective observational study included 106 patients with amblyopia who received OMS therapy. A 20-session course (30 minutes per session) was prescribed; actual treatment exposure varied and averaged 5.17 sessions. We assessed outcomes at the last available post-treatment visit (mean follow-up, 36.79 days; median, one day). We compared pre- and post-treatment visual acuity, stereopsis, central macular thickness (CMT) and retinal nerve fibre layer (RNFL) thickness. We performed regression analyses to identify factors associated with the final visual outcome.
RESULTS: Study participants' mean age was 17.55 ± 13.91 years. Refractive amblyopia was the most common subtype (67.9%), followed by strabismic amblyopia (30.2%). Mean amblyopic-eye visual acuity improved from 0.97 ± 0.53 to 0.75 ± 0.52 logarithm of the minimum angle of resolution (logMAR) (p < 0.001). Distance stereopsis improved significantly from 349.24 ± 281.62 to 291.05 ± 271.96 arc seconds (p < 0.001), while near stereopsis remained unchanged (p = 0.261). Optical coherence tomography (OCT) showed no clinically meaningful change in RNFL thickness. A small increase in amblyopic-eye CMT was statistically significant (mean change, 6.87 µm; p = 0.013) but was not associated with visual improvement and was considered of uncertain clinical relevance. Baseline visual acuity was the strongest predictor of outcome (β = 0.82, p < 0.001). Greater treatment exposure was independently associated with better visual recovery (β = -0.021, p = 0.014), whereas age, follow-up duration and amblyopia subtype were not significant predictors.
CONCLUSION: Orthoptek Magnocellular Stimulator therapy was associated with improved visual acuity and distance stereopsis. Retinal nerve fibre layer thickness remained stable, while the small statistically significant increase in amblyopic-eye CMT was not associated with visual improvement and had uncertain clinical significance. The absence of an age-related association suggests that visual improvement may be achievable beyond the traditional critical period. These preliminary findings support further controlled evaluation of OMS as a potential adjunct to amblyopia rehabilitation in younger and older patients.
METHODS: This prospective observational study included 106 patients with amblyopia who received OMS therapy. A 20-session course (30 minutes per session) was prescribed; actual treatment exposure varied and averaged 5.17 sessions. We assessed outcomes at the last available post-treatment visit (mean follow-up, 36.79 days; median, one day). We compared pre- and post-treatment visual acuity, stereopsis, central macular thickness (CMT) and retinal nerve fibre layer (RNFL) thickness. We performed regression analyses to identify factors associated with the final visual outcome.
RESULTS: Study participants' mean age was 17.55 ± 13.91 years. Refractive amblyopia was the most common subtype (67.9%), followed by strabismic amblyopia (30.2%). Mean amblyopic-eye visual acuity improved from 0.97 ± 0.53 to 0.75 ± 0.52 logarithm of the minimum angle of resolution (logMAR) (p < 0.001). Distance stereopsis improved significantly from 349.24 ± 281.62 to 291.05 ± 271.96 arc seconds (p < 0.001), while near stereopsis remained unchanged (p = 0.261). Optical coherence tomography (OCT) showed no clinically meaningful change in RNFL thickness. A small increase in amblyopic-eye CMT was statistically significant (mean change, 6.87 µm; p = 0.013) but was not associated with visual improvement and was considered of uncertain clinical relevance. Baseline visual acuity was the strongest predictor of outcome (β = 0.82, p < 0.001). Greater treatment exposure was independently associated with better visual recovery (β = -0.021, p = 0.014), whereas age, follow-up duration and amblyopia subtype were not significant predictors.
CONCLUSION: Orthoptek Magnocellular Stimulator therapy was associated with improved visual acuity and distance stereopsis. Retinal nerve fibre layer thickness remained stable, while the small statistically significant increase in amblyopic-eye CMT was not associated with visual improvement and had uncertain clinical significance. The absence of an age-related association suggests that visual improvement may be achievable beyond the traditional critical period. These preliminary findings support further controlled evaluation of OMS as a potential adjunct to amblyopia rehabilitation in younger and older patients.